{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:58:07Z","timestamp":1790146687460,"version":"4.0.1"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jconrel.2024.11.061","type":"journal-article","created":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T19:39:45Z","timestamp":1732995585000},"page":"661-674","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Nanoparticulate drug combination inhibits DNA damage repair and PD-L1 expression in BRCA-mutant and wild type triple-negative breast cancer"],"prefix":"10.1016","volume":"377","author":[{"given":"Ibrahim","family":"Alradwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Zhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HoYin","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulmottaleb","family":"Zetrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunsheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey T.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Rauth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao Yu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2024.11.061_bb0005","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00432-018-2644-2","article-title":"Patterns of breast cancer relapse in accordance to biological subtype","volume":"144","author":"Ignatov","year":"2018","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0010","doi-asserted-by":"crossref","first-page":"412","DOI":"10.5306\/wjco.v5.i3.412","article-title":"Biological subtypes of breast cancer: prognostic and therapeutic implications","volume":"5","author":"Yersal","year":"2014","journal-title":"World J. Clin. Oncol."},{"issue":"Suppl. 2","key":"10.1016\/j.jconrel.2024.11.061_bb0015","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.3816\/CBC.2009.s.008","article-title":"Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer","volume":"9","author":"Anders","year":"2009","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.jconrel.2024.11.061_bb0020","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-019-1443-1","article-title":"Recent advances in nanotheranostics for triple negative breast cancer treatment","volume":"38","author":"Thakur","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0025","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1038\/s41598-017-07617-7","article-title":"H-ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer","volume":"7","author":"Mazzucchelli","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0030","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41523-023-00579-2","article-title":"Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer","volume":"9","author":"Fabi","year":"2023","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.jconrel.2024.11.061_bb0035","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1021\/acs.molpharmaceut.2c00038","article-title":"Advances in nanomedicine design: multidisciplinary strategies for unmet medical needs","volume":"19","author":"Ahmed","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0040","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.addr.2018.07.007","article-title":"Tumor targeting via EPR: strategies to enhance patient responses","volume":"130","author":"Golombek","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2021","key":"10.1016\/j.jconrel.2024.11.061_bb0045","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1515\/mr-2021-0011","article-title":"Nano drug delivery systems improve metastatic breast cancer therapy","volume":"1","author":"Zhu","year":"2021","journal-title":"Med. Rev."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0050","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/aps.2018.33","article-title":"Importance of integrating nanotechnology with pharmacology and physiology for innovative drug delivery and therapy \u2013 an illustration with firsthand examples","volume":"39","author":"Zhang","year":"2018","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0055","first-page":"93","article-title":"Triple-negative breast cancer: treatment challenges and solutions","volume":"8","author":"Collignon","year":"2016","journal-title":"Breast Cancer"},{"key":"10.1016\/j.jconrel.2024.11.061_bb0060","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1023\/A:1008365716693","article-title":"Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg\/m2","volume":"11","author":"Safra","year":"2000","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0065","article-title":"DNA repair pathways in cancer therapy and resistance","volume":"11","author":"Li","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0070","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Koboldt","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2024.11.061_bb0075","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1158\/0008-5472.CAN-12-1699","article-title":"Genetic susceptibility to triple-negative breast cancer","volume":"73","author":"Stevens","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2018.12.002","article-title":"PARP inhibitors in ovarian cancer","volume":"73","author":"Franzese","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0085","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/emmm.200900041","article-title":"Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors","volume":"1","author":"Mendes-Pereira","year":"2009","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0090","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0095","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2024.11.061_bb0100","doi-asserted-by":"crossref","first-page":"17041","DOI":"10.1073\/pnas.1305170110","article-title":"Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance","volume":"110","author":"Johnson","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0105","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.tcb.2019.07.008","article-title":"PARP inhibitor resistance: a tug-of-war in BRCA-mutated cells","volume":"29","author":"Noordermeer","year":"2019","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0110","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.dnarep.2018.08.021","article-title":"Mechanisms of PARP inhibitor sensitivity and resistance","volume":"71","author":"D\u2019Andrea","year":"2018","journal-title":"DNA Repair"},{"key":"10.1016\/j.jconrel.2024.11.061_bb0115","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0120","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","article-title":"Understanding and overcoming resistance to PARP inhibitors in cancer therapy","volume":"18","author":"Dias","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061502","article-title":"Combined PARP inhibition and immune checkpoint therapy in solid tumors","volume":"12","author":"Peyraud","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2024.11.061_bb0130","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102090","article-title":"Targeting the DNA damage response for patients with lymphoma: preclinical and clinical evidences","volume":"90","author":"Carrassa","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0140","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.47006","article-title":"Cancer drug price and novelty in mechanism of action","volume":"6","author":"Miljkovic","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jconrel.2024.11.061_bb0145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.matbio.2016.10.001","article-title":"Roles and targeting of the HAS\/hyaluronan\/CD44 molecular system in cancer","volume":"59","author":"Karousou","year":"2017","journal-title":"Matrix Biol."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0150","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.drup.2008.04.002","article-title":"Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance","volume":"11","author":"Toole","year":"2008","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0155","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/103923","article-title":"Hyaluronan and RHAMM in wound repair and the \u201ccancerization\u201d of stromal tissues","volume":"2014","author":"Tolg","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0160","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00201","article-title":"Interactions between Hyaluronan and its receptors (CD44, RHAMM) regulate the activities of inflammation and cancer","volume":"6","author":"Misra","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0165","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.tips.2007.08.005","article-title":"PARP-1 activation in the ERK signaling pathway","volume":"28","author":"Cohen-Armon","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0170","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.1073\/pnas.0914242107","article-title":"Nuclear phosphoinositide 3-kinase \u03b2 controls double-strand break DNA repair","volume":"107","author":"Kumar","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2021.110229","article-title":"Therapeutic potential of the PI3K inhibitor LY294002 and PARP inhibitor Talazoparib combination in BRCA-deficient triple negative breast cancer cells","volume":"91","author":"Guney Eskiler","year":"2022","journal-title":"Cell. Signal."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0180","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal5148","article-title":"Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers","volume":"9","author":"Sun","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0185","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/ijc.31357","article-title":"IFN-\u03b3 mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling","volume":"143","author":"Gao","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2024.11.061_bb0190","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/path.5280","article-title":"MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells","volume":"249","author":"Stutvoet","year":"2019","journal-title":"J. Pathol."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0195","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3389\/fimmu.2015.00201","article-title":"Interactions between Hyaluronan and its receptors (CD44, RHAMM) regulate the activities of inflammation and cancer","volume":"6","author":"Misra","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0200","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.3390\/molecules19033193","article-title":"Hyaluronic acid conjugates as vectors for the active targeting of drugs, genes and nanocomposites in cancer treatment","volume":"19","author":"Arpicco","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2024.11.061_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.800481","article-title":"CD44-targeted nanocarrier for cancer therapy","volume":"12","author":"Kesharwani","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0210","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1158\/0008-5472.CAN-09-0143","article-title":"Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-CD44 interactions with small hyaluronan oligosaccharides","volume":"69","author":"Slomiany","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0215","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/ijc.23122","article-title":"Hyaluronan oligosaccharides sensitize lymphoma resistant cell lines to vincristine by modulating P-glycoprotein activity and PI3K\/Akt pathway","volume":"122","author":"Laura","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2024.11.061_bb0220","first-page":"1822","article-title":"Targeting gallbladder cancer: hyaluronan sensitizes cancer cells to chemo-therapeutics","volume":"8","author":"Ma","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0225","doi-asserted-by":"crossref","first-page":"6829","DOI":"10.1016\/j.biomaterials.2013.05.036","article-title":"The use of HA oligosaccharide-loaded nanoparticles to breach the endogenous hyaluronan glycocalyx for breast cancer therapy","volume":"34","author":"Yang","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2024.11.061_bb0230","first-page":"15","article-title":"Doxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116 cells, opposite to its effects on MDA-MB-231 cells","volume":"44","author":"Naba","year":"2020","journal-title":"Turk. J. Biol."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0235","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.bbrc.2019.11.106","article-title":"Doxorubicin inhibits PD-L1 expression by enhancing TTP-mediated decay of PD-L1 mRNA in cancer cells","volume":"522","author":"Kim","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0240","doi-asserted-by":"crossref","first-page":"2100022","DOI":"10.1002\/adtp.202100022","article-title":"Targeting signaling pathways of hyaluronic acid and integrin receptors by synergistic combination nanocomposites inhibits systemic metastases and primary triple negative breast cancer","volume":"4","author":"Zhang","year":"2021","journal-title":"Adv. Therapeut."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0245","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13346-014-0210-2","article-title":"RGD-conjugated solid lipid nanoparticles inhibit adhesion and invasion of \u03b1v\u03b23 integrin-overexpressing breast cancer cells","volume":"5","author":"Shan","year":"2015","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0250","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ccr.2009.10.013","article-title":"Tissue-penetrating delivery of compounds and nanoparticles into tumors","volume":"16","author":"Sugahara","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2024.11.061_bb0255","doi-asserted-by":"crossref","first-page":"1900543","DOI":"10.1002\/adhm.201900543","article-title":"Multitargeted nanoparticles deliver synergistic drugs across the blood\u2013brain barrier to brain metastases of triple negative breast cancer cells and tumor-associated macrophages","volume":"8","author":"Zhang","year":"2019","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0260","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15112906","article-title":"Metastatic breast Cancer: review of emerging Nanotherapeutics","volume":"15","author":"Dissanayake","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2024.11.061_bb0265","doi-asserted-by":"crossref","first-page":"9925","DOI":"10.1021\/nn501069c","article-title":"A multifunctional polymeric nanotheranostic system delivers doxorubicin and imaging agents across the blood-brain barrier targeting brain metastases of breast cancer","volume":"8","author":"Li","year":"2014","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2024.11.061_bb0270","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/adhm.201200006","article-title":"A novel solid lipid nanoparticle formulation for active targeting to tumor alpha(v) beta(3) integrin receptors reveals cyclic RGD as a double-edged sword","volume":"1","author":"Shuhendler","year":"2012","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0275","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13346-014-0210-2","article-title":"RGD-conjugated solid lipid nanoparticles inhibit adhesion and invasion of alphavbeta3 integrin-overexpressing breast cancer cells","volume":"5","author":"Shan","year":"2015","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0280","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/pi.4244","article-title":"Characterization of novel soybean-oil-based thermosensitive amphiphilic polymers for drug delivery applications","volume":"61","author":"Abdekhodaie","year":"2012","journal-title":"Polym. Int."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0285","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/aps.2016.166","article-title":"Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice","volume":"38","author":"Zhang","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0290","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1021\/mp500093c","article-title":"Synergistic nanoparticulate drug combination overcomes multidrug resistance, increases efficacy, and reduces cardiotoxicity in a nonimmunocompromised breast tumor model","volume":"11","author":"Shuhendler","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131285","article-title":"Evaluation of MCF10A as a reliable model for Normal human mammary epithelial cells","volume":"10","author":"Qu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2024.11.061_bb0300","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.bbrc.2018.03.169","article-title":"Integrin expression and glycosylation patterns regulate cell-matrix adhesion and alter with breast cancer progression","volume":"499","author":"Singh","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0305","doi-asserted-by":"crossref","first-page":"16667","DOI":"10.1074\/jbc.M702078200","article-title":"The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells","volume":"282","author":"Hamilton","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0310","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP inhibitor upregulates PD-L1 expression and enhances Cancer-associated immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0315","first-page":"215","article-title":"PARP inhibitors: review of mechanisms of action and BRCA1\/2 mutation targeting","volume":"15","author":"Dziadkowiec","year":"2016","journal-title":"Przeglad Menopauzalny"},{"key":"10.1016\/j.jconrel.2024.11.061_bb0320","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s43018-020-00148-7","article-title":"Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer","volume":"2","author":"Mehta","year":"2021","journal-title":"Nat. Can."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0325","doi-asserted-by":"crossref","first-page":"37450","DOI":"10.1038\/srep37450","article-title":"Endothelial cell colony forming units derived from malignant breast diseases are resistant to tumor necrosis factor-\u03b1-induced apoptosis","volume":"6","author":"Chou","year":"2016","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.jconrel.2024.11.061_bb0330","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1111\/febs.15588","article-title":"Enhanced DNA damage response through RAD50 in triple negative breast cancer resistant and cancer stem-like cells contributes to chemoresistance","volume":"288","author":"Abad","year":"2020","journal-title":"FEBS J."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0335","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1667\/RR13515.1","article-title":"DNA damage response genes and the development of cancer metastasis","volume":"181","author":"Broustas","year":"2014","journal-title":"Radiat. Res."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0340","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.canlet.2011.12.025","article-title":"Use of the \u03b3-H2AX assay to monitor DNA damage and repair in translational cancer research","volume":"327","author":"Ivashkevich","year":"2012","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0345","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0076-6879(08)01606-6","article-title":"DNA damage response and apoptosis","volume":"446","author":"Plesca","year":"2008","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0350","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.molcel.2006.12.012","article-title":"DNA-independent PARP-1 activation by phosphorylated ERK2 increases Elk1 activity: a link to histone acetylation","volume":"25","author":"Cohen-Armon","year":"2007","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jconrel.2024.11.061_bb0355","doi-asserted-by":"crossref","first-page":"7136","DOI":"10.1073\/pnas.0508606103","article-title":"Direct phosphorylation and regulation of poly(ADP-ribose) polymerase-1 by extracellular signal-regulated kinases 1\/2","volume":"103","author":"Kauppinen","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0360","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/09553000110069317","article-title":"MAPK dependence of DNA damage repair: ionizing radiation and the induction of expression of the DNA repair genes XRCC1 and ERCC1 in DU145 human prostate carcinoma cells in a MEK1\/2 dependent fashion","volume":"77","author":"Yacoub","year":"2001","journal-title":"Int. J. Radiat. Biol."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0365","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.tips.2007.08.005","article-title":"PARP-1 activation in the ERK signaling pathway","volume":"28","author":"Cohen-Armon","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0370","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.gpb.2016.05.001","article-title":"Functions of PARylation in DNA damage repair pathways","volume":"14","author":"Wei","year":"2016","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"10.1016\/j.jconrel.2024.11.061_bb0375","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/0008-5472.CAN-14-3362","article-title":"Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer","volume":"76","author":"Lastwika","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0380","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/onc.2008.384","article-title":"PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer","volume":"28","author":"Crane","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2024.11.061_bb0385","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nm1517","article-title":"Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma","volume":"13","author":"Parsa","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0390","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1038\/s41467-022-29335-z","article-title":"Modification of BRCA1-associated breast cancer risk by HMMR overexpression","volume":"13","author":"Mateo","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0395","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001199","article-title":"Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer","volume":"9","author":"Maxwell","year":"2011","journal-title":"PLoS Biol."},{"key":"10.1016\/j.jconrel.2024.11.061_bb0400","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/cncr.11083","article-title":"Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor","volume":"97","author":"Chang","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2024.11.061_bb0405","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1200\/JCO.22.02572","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"41","author":"Liedtke","year":"2023","journal-title":"J. Clin. Oncol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924008204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924008204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T21:29:50Z","timestamp":1734643790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924008204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":81,"alternative-id":["S0168365924008204"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.11.061","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanoparticulate drug combination inhibits DNA damage repair and PD-L1 expression in BRCA-mutant and wild type triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.11.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}